drugset / Trial / NCT01226485
A Study in Advanced Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find a recommended dose level and schedule of dosing LY2940680 that can safely be taken by participants with advanced cancer. The study will also explore the changes in a cancer marker level in skin, hair follicles, buccal cells, and tumor cells. Finally, the study will help document any antitumor activity this drug may have.
Timeline
- Start
- 2010-09
- Primary completion
- 2015-01
- Completion
- 2017-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | taladegib | Small molecule | 50 mg | Oral |
| Subject | taladegib | Small molecule | 100 mg | Oral |
| Subject | taladegib | Small molecule | 200 mg | Oral |
| Subject | taladegib | Small molecule | 400 mg | Oral |
| Subject | taladegib | Small molecule | 600 mg | Oral |
Indications
No indication recorded.